683 Capital Management, LLC
About 683 Capital Management, LLC’s 13F portfolio
683 Capital Management, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , 683 Capital Management, LLC reported $1.1B across 128 US-listed positions (). Its largest position is CAPITAL ONE FINL CORP (COF) at 6.7% of the reported book, and its ten biggest holdings make up 39% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NYSE: COF CAPITAL ONE FINL CORP | — — | 6.7% | 365K | $73.2M |
| 2 | NYSE: CVNA CARVANA CO | — — | 4.5% | 750K | $49.4M |
| 3 | NASDAQ: ANAB ANAPTYSBIO INC | — — | 4.1% | 660K | $44.6M |
| 4 | NASDAQ: KSPI KASPI KZ JSC | — — | 3.7% | 470K | $40.7M |
| 5 | NASDAQ: BBIO BRIDGEBIO PHARMA INC | — — | 3.6% | 21.8M | $38.8M |
| 6 | NYSE: BDX BECTON DICKINSON & CO | — — | 3.5% | 250K | $37.8M |
| 7 | NYSE: MOH MOLINA HEALTHCARE INC | — — | 3.5% | 165K | $37.7M |
| 8 | NYSE: HGV HILTON GRAND VACATIONS INC | — — | 3.3% | 690K | $36.1M |
| 9 | NASDAQ: PTGX PROTAGONIST THERAPEUTICS INC | — — | 3.3% | 290K | $35.5M |
| 10 | NASDAQ: MGTX MEIRAGTX HLDGS PLC | — — | 2.9% | 2.3M | $31.1M |
| 11 | NASDAQ: WVE WAVE LIFE SCIENCES LTD | — — | 2.6% | 5.0M | $28.8M |
| 12 | NASDAQ: QURE UNIQURE NV | — — | 2.4% | 575K | $26.5M |
| 13 | NASDAQ: AMLX AMYLYX PHARMACEUTICALS INC | — — | 2.1% | 1.3M | $23.0M |
| 14 | NYSE: AMTM AMENTUM HOLDINGS INC | — — | 2.1% | 1.1M | $22.7M |
| 15 | NASDAQ: TGTX TG THERAPEUTICS INC | — — | 2.0% | 389K | $21.4M |
| 16 | NASDAQ: PHAT PHATHOM PHARMACEUTICALS INC | — — | 1.8% | 1.9M | $20.1M |
| 17 | NYSE: U UNITY SOFTWARE INC | — — | 1.6% | 615K | $17.6M |
| 18 | NYSE: WAL WESTERN ALLIANCE BANCORP | — — | 1.5% | 200K | $16.4M |
| 19 | NYSE: IAG IAMGOLD CORP | — — | 1.5% | 1.0M | $16.0M |
| 20 | NYSE: ELV ELEVANCE HEALTH INC FORMERLY | — — | 1.4% | 40K | $15.5M |
| 21 | NASDAQ: TRAX FIRST TRACKS BIOTHERAPEUTICS | — — | 1.4% | 750K | $15.1M |
| 22 | NYSE: KNOP KNOT OFFSHORE PARTNERS LP | — — | 1.4% | 1.5M | $15.0M |
| 23 | NASDAQ: SRPT SAREPTA THERAPEUTICS INC | — — | 1.3% | 783K | $14.1M |
| 24 | NYSE: UNH UNITEDHEALTH GROUP INC | — — | 1.2% | 32K | $13.3M |
| 25 | NYSE: SE SEA LTD | — — | 1.2% | 135K | $12.9M |
Showing 1–25 of 128 positions on this page reported in this 13F.
- Healthcare48%
- Consumer Cyclical14%
- Financial Services12%
- Technology5.4%
- Industrials4.6%
- Basic Materials4.3%
- Energy3.8%
- Communication Services3.0%
- Real Estate1.5%
- Consumer Defensive0.3%
- AddedCVNACARVANA CO+384%$49.4M
- AddedANABANAPTYSBIO INC+5.6%$44.6M
- AddedBDXBECTON DICKINSON & CO+11.1%$37.8M
- AddedMOHMOLINA HEALTHCARE INC+3.1%$37.7M
- AddedWVEWAVE LIFE SCIENCES LTD+1.0%$28.8M
- AddedQUREUNIQURE NV+15.0%$26.5M
- AddedAMTMAMENTUM HOLDINGS INC+41.9%$22.7M
- NewUUNITY SOFTWARE INC—$17.6M
- NewTRAXFIRST TRACKS BIOTHERAPEUTICS—$15.1M
- AddedKNOPKNOT OFFSHORE PARTNERS LP+1.7%$15.0M
- ReducedCOFCAPITAL ONE FINL CORP−2.7%$73.2M
- ReducedKSPIKASPI KZ JSC−1.1%$40.7M
- ReducedHGVHILTON GRAND VACATIONS INC−11.0%$36.1M
- ReducedPTGXPROTAGONIST THERAPEUTICS INC−18.3%$35.5M
- ReducedMGTXMEIRAGTX HLDGS PLC−6.1%$31.1M
- ReducedAMLXAMYLYX PHARMACEUTICALS INC−16.4%$23.0M
- ReducedTGTXTG THERAPEUTICS INC−34.1%$21.4M
- ReducedWALWESTERN ALLIANCE BANCORP−11.1%$16.4M
- ReducedIAGIAMGOLD CORP−3.8%$16.0M
- ReducedGOOGLALPHABET INC−2.8%$12.5M
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | RNAQ Rainier Acquisition Corporation | 13G | 11.2% | 863K | Filed 03 SEP 2026 |
| 2 | GOSS Gossamer Bio, Inc. | 13G | 10.0% · 2 classes | 49.9M | Filed 11 JUN 2026 |
| 3 | MREO Mereo BioPharma Group plc | 13G | 8.2% | 65.1M | Filed 06 JAN 2026 |
| 4 | INAB IN8BIO, INC. | 13G | 7.9% | 770K | Filed 30 DEC 2025 |
| 5 | PCSC Perceptive Capital Solutions Corp | 13G | 7.2% | 641K | Filed 17 FEB 2026 |
| 6 | — Mersana Therapeutics, Inc. | 13G | 7.0% | 351K | Filed 17 FEB 2026 |
| 7 | GUTS FRACTYL HEALTH, INC. | 13G | 5.3% | 7.1M | Filed 14 OCT 2025 |
Showing all 7 disclosed stakes. 1 last disclosed over a year ago (the holder may since have dropped below 5%).
Reading 683 Capital Management, LLC’s 13F portfolio
683 Capital Management, LLC’s $1.1B 13F book is spread across 128 reported positions and is moderately diversified, the ten largest names accounting for 39%. There are meaningful positions at the top alongside a long tail of smaller holdings. Its five largest positions are COF, CVNA, ANAB, KSPI and BBIO, led by CAPITAL ONE FINL CORP (COF) at 6.7% of the portfolio. The heaviest sector exposure is Healthcare (48%), then Consumer Cyclical (14%).
What 683 Capital Management, LLC changed last quarter
Between 2026-03-31 and Q2 2026, 683 Capital Management, LLC was a net seller: it opened 19 new positions and added to 29 more, while trimming 37 and closing 99 outright. Against a 128-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was CARVANA CO (CVNA), and its biggest reduction was CAPITAL ONE FINL CORP (COF).
What a 13F does and doesn’t reveal
A 13F captures only 683 Capital Management, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names 683 Capital Management, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. 683 Capital Management, LLC's profile on this page is built directly from those filings.
How current is the 13F data on 683 Capital Management, LLC's page?
It reflects 683 Capital Management, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When 683 Capital Management, LLC files its next quarterly report, this page refreshes automatically.
Can I see 683 Capital Management, LLC's complete list of holdings?
This page highlights 683 Capital Management, LLC's largest positions rather than all 128 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under 683 Capital Management, LLC's filings.
Does a 13F show everything 683 Capital Management, LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of 683 Capital Management, LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why 683 Capital Management, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

